Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Warner

Showing results (141-150 of 159) with videos related to

Pageof 16
Sort By:
Nature Communications|September 26, 2025
High expression of Rex-orf-I and HBZ mRNAs and bronchiectasis in lung of HTLV-1A/C infected macaquesSarkis Sarkis, Anna Gutowska, Mohammad Arif Rahman, et al.
Cancer|May 24, 2023
Stereotactic ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocolBiniam Kidane, Ian J Gerard, Jonathan Spicer, et al.
European Urology Oncology|July 10, 2024
Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the KidneyVivian S Tan, Rohann J M Correa, Andrew Warner, et al.
BMC Cancer|August 21, 2019
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trialDavid A Palma, Robert Olson, Stephen Harrow, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2025
Efficacy of Stereotactic Ablative Body Radiotherapy (SABR) in uncommon subtypes of primary kidney cancer: An analysis from the International Radiosurgery Oncology Consortium of the KidneyMuhammad Ali, Rohann J M Correa, David Pryor, et al.
JAMA Oncology|March 7, 2024
Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical TrialDavid A Palma, Houda Bahig, Andrew Hope, et al.
International Journal of Radiation Oncology, Biology, Physics|September 5, 2025
Dosimetric Outcomes of SBRT to Ultra-central Lung Tumors: Lessons from the SUNSET trialRohan Salunkhe, David A Palma, Andrew Warner, et al.
The Lancet. Oncology|February 5, 2026
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaborationChad Tang, Alex D Sherry, Hyunsoo Hwang, et al.
BMC Palliative Care|September 7, 2024
A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocolDavid A Palma, Meredith E Giuliani, Rohann J M Correa, et al.
The Lancet. Oncology|August 17, 2019
Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
Pageof 16

Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
Nature Communications|September 26, 2025
High expression of Rex-orf-I and HBZ mRNAs and bronchiectasis in lung of HTLV-1A/C infected macaquesSarkis Sarkis, Anna Gutowska, Mohammad Arif Rahman, et al.
Cancer|May 24, 2023
Stereotactic ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocolBiniam Kidane, Ian J Gerard, Jonathan Spicer, et al.
European Urology Oncology|July 10, 2024
Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the KidneyVivian S Tan, Rohann J M Correa, Andrew Warner, et al.
BMC Cancer|August 21, 2019
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trialDavid A Palma, Robert Olson, Stephen Harrow, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2025
Efficacy of Stereotactic Ablative Body Radiotherapy (SABR) in uncommon subtypes of primary kidney cancer: An analysis from the International Radiosurgery Oncology Consortium of the KidneyMuhammad Ali, Rohann J M Correa, David Pryor, et al.
JAMA Oncology|March 7, 2024
Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical TrialDavid A Palma, Houda Bahig, Andrew Hope, et al.
International Journal of Radiation Oncology, Biology, Physics|September 5, 2025
Dosimetric Outcomes of SBRT to Ultra-central Lung Tumors: Lessons from the SUNSET trialRohan Salunkhe, David A Palma, Andrew Warner, et al.
The Lancet. Oncology|February 5, 2026
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaborationChad Tang, Alex D Sherry, Hyunsoo Hwang, et al.
BMC Palliative Care|September 7, 2024
A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocolDavid A Palma, Meredith E Giuliani, Rohann J M Correa, et al.
The Lancet. Oncology|August 17, 2019
Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
Pageof 16